Domantis Limited

Medical Research Council

Glaxo Group Limited

Armin Sepp

Gregory Paul Winter

Andrew David Griffiths

Steve Holmes

Ian M Tomlinson

Benjamin P Woolven

Rudolf M T De Wildt

Justian Craig Fox

Mary Frances Fitzgerald

Jennifer Luckett

Dan S Tawfik

Adriaan Allart Stoop

Inusha De Silva

Dan The Weizmann Institute Of Science Tawfik

Andrew Mrc Laboratory Of Molecular Griffiths

Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.

Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue

The invention relates to storage-stable anti-TNFR1 antibody single variable domains (dAbs), antagonists and multispecific ligands, as well as methods and uses of these. The anti-TNFR1 polypeptides, antibody single variable domains (dAbs), antagonists and multispecific ligands are useful for treating and/or preventing inflammatory disease, such as arthritis or COPD, as well as for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient.

Stable anti-TNFR1 polypeptides, antibody variable domains and antagonists

Agents that bind a target in pulmonary tissue for targeting respiratory diseases

The present invention to a nucleotide sequence encoding one or more Arc DNA binding domains, one or more Arc DNA binding sites and at least one polypeptide domain.

Selection

The invention describes a method for isolating one or more genetic elements encoding a gene product having a desired activity, comprising the steps of: (a) compartmentalising genetic elements into microcapsules; (b) expressing the genetic elements to produce their respective gene products within the microcapsules; (c) sorting the genetic elements which produce the gene product having the desired activity using a change in the optical properties of the genetic elements. The invention enables the in vitro evolution of nucleic acids and proteins by repeated mutagenesis and iterative applications of the method of the invention.

Optical sorting method

Growing community of inventors

Cambridge, United Kingdom

Armin Sepp